CCR4 and primary cutaneous T-cell non-Hodgkin lymphoma: Structural Insights into the ADCC Mechanism and Resistance of Mogamulizumab, a First-in-Class Anti-CCR4 Therapy for Cutaneous T Cell Lymphoma